Market Newsdesk

MIAMI, June 18, 2026 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimer’s disease has been accepted for Poster Presentation at the 2026 Alzheimer’s Association International Conference^® (AAIC^®), to be held July 12-15, 2026 in London, United Kingdom and online.

Results from the CLEAR MIND Phase 2a clinical trial, which support the therapeutic potential of laromestrocel in the treatment of mild Alzheimer’s disease and provided evidence-based support for further clinical development, were published in the peer-reviewed journal Nature Medicine in March 2025.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B^™), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is pursuing four pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, Pediatric Dilated Cardiomyopathy (DCM) and Aging-related Frailty. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program – Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program – Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation. For more information, visit www.longeveron.com or follow Longeveron on LinkedIn, X, and Instagram.

Forward-Looking Statements

Certain statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve known and unknown risks, uncertainties, and other important factors that could cause actual results, performance, or achievements to differ materially from those anticipated, expressed, or implied by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expects,” “intend,” “looks to,” “may,” “on condition,” “plan,” “potential,” “predict,” “preliminary,” “project,” “see,” “should,” “target,” “will,” “would,” or the negative thereof or comparable terminology, although not all forward-looking statements contain these words, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; our ability to successfully transition toward a more capital-efficient, asset-light operating model; our ability to secure one or more strategic licensing partnerships for our stem cell therapy laromestrocel in our development programs; the ability to reach alignment with the FDA on a potential path toward regulatory approval; receipt of trial results and other available evidence sufficient to support the Company filing a BLA following the readout of top-line results of the ELPIS II data; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; market and other conditions, our cash position and need to raise additional capital, the difficulties we may face in obtaining access to capital, and the dilutive impact it may have on our investors; our financial performance, and ability to continue as a going concern; the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; the ability of our clinical trials to demonstrate safety and efficacy of our investigational product candidates, and other positive results; the timing and focus of our ongoing and future preclinical studies and clinical trials, and the reporting of data from those studies and trials; the size of the market opportunity for certain of our investigational product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; our ability to scale production and commercialize the investigational product candidate for certain indications; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of our investigational product candidates; our ability to obtain and maintain regulatory approval of our investigational product candidates in the U.S. and other jurisdictions; our plans relating to the further development of our investigational product candidates, including additional disease states or indications we may pursue; our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and our ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and our ability to attract and retain such personnel; and our estimates regarding expenses, future revenue, capital requirements and needs for additional financing.

Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. The Company operates in highly competitive and rapidly changing environment; therefore, new factors may arise, and it is not possible for the Company’s management to predict all such factors that may arise nor assess the impact of such factors or the extent to which any individual factor or combination thereof, may cause results to differ materially from those contained in any forward-looking statements. The forward-looking statements contained in this press release are made as of the date of this press release based on information available as of the date of this press release, are inherently uncertain, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor and Media Contact:

Derek Cole
Investor Relations Advisory Solutions
[email protected]

SAN DIEGO, June 18, 2026 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions, today announced that President and Chief Executive Officer, Sabrina Martucci Johnson, will participate in multiple speaking engagements and deliver a Company corporate presentation during the BIO International Convention 2026, taking place June 22-25 in San Diego, California.

As one of the biotechnology industry’s premier global gatherings, BIO International Convention brings together thousands of executives, investors, innovators, policymakers and strategic partners to shape the future of healthcare. Daré’s participation underscores the Company’s growing leadership role in advancing innovation for women and accelerating the development of solutions that have historically been underrepresented in healthcare.

“Women’s health represents one of the largest and most underserved opportunities in healthcare today,” said Ms. Johnson. “BIO International Convention provides an exceptional platform to engage with global industry leaders, investors and potential collaborators who share a commitment to advancing innovation and improving health outcomes. We are excited to highlight Daré’s progress and discuss how our differentiated portfolio is positioned to address significant unmet needs while creating meaningful value for patients, partners and shareholders.”

Details of the Company’s participation at BIO International Convention 2026 are as follows:

Invest in San Diego Breakfast

Date: Monday, June 22, 2026
Time: 7:30 – 9:30 a.m. PT
Location: IQHQ, 975 Waterfront Place, San Diego, California

Ms. Johnson will participate as a featured speaker during the breakfast program, which highlights the San Diego region’s life sciences ecosystem and brings together biotechnology executives, investors and industry stakeholders.

WIB@BIO 2026 Executive Breakfast: Sparking Greatness — Leading Through Inspiration

Date: Monday, June 22, 2026
Time: 9:00 – 11:00 a.m. PT
Location: RaDD (IQHQ), 6th Floor, 925 Waterfront Place, San Diego, California

Ms. Johnson will join fellow biotechnology leaders for a discussion focused on leadership, mentorship and fostering innovation across the industry.

BIO International Convention Corporate Presentation

Date: Tuesday, June 23, 2026
Time: 3:30 p.m. PT
Location: Theater 4

Ms. Johnson will discuss Daré Bioscience’s corporate strategy, commercial and development portfolio and upcoming milestones, highlighting the Company’s commitment to delivering impactful solutions that seek to address critical gaps in women’s healthcare.

Are We There Yet: The Road to Clinical Development in Women’s Health

Date: Wednesday, June 24, 2026
Time: 4:15 – 5:15 p.m. PT
Location: Room 26AB

Ms. Johnson will join industry leaders and women’s health advocates for a discussion examining the challenges and opportunities in advancing clinical development for women’s health products. The session will explore pathways to accelerate innovation, improve patient access and address longstanding gaps in women’s healthcare research and development.

Investors and conference attendees interested in meeting with Daré management during the BIO International Convention are encouraged to contact the Company to arrange a meeting. For more information, please visit the convention website.

ABOUT DARÉ BIOSCIENCE, INC.

Daré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation Daré advances is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, Daré is working to close critical gaps in care using science that serves her needs. For decades, women have been told to “wait it out” or “live with it,” while innovations that could improve their quality of life languish in the regulatory or funding pipeline. With growing awareness around menopause, sexual health, and vaginal health, the conversation is shifting. However, access to proven solutions is lagging. Daré is working to change that. Learn more at darebioscience.com.

CONTACT:
Daré Bioscience Investor Relations
[email protected]

NETANYA, Israel, June 18, 2026 (GLOBE NEWSWIRE) — BiomX Inc. (NYSE American: PHGE), a company that develops and acquires technologies for defense, security, and first-response markets, today announced that it has posted an updated informational presentation to the Company’s website as part of its completed strategic transition towards the defense sector. The presentation provides an overview of BiomX’s portfolio, operating framework, leadership and advisory team, and growth strategy.

BiomX’s current strategy is built around the growing need for technologies that can identify, analyze, and support faster responses to physical threats across high-consequence settings. The Company’s portfolio currently includes Zorronet, an AI-powered Autonomous Command Center platform, and DFSL, which develops laser-based threat detection and physical security technologies.

“Our new presentation is intended to give stockholders and investors a clear view of BiomX as it exists today, and a sense of how we are working to build the Company from here,” said Michael Oster, Chief Executive Officer of BiomX. “Over the past several months, we have completed a fundamental strategic transition and rebuilt the Company around defense, security, and critical-infrastructure technologies. Our focus now is on building a portfolio that helps identify, analyze, and respond to physical threats more quickly, particularly as UAVs and autonomous systems create new challenges for governments, infrastructure operators, and security teams. We are also focused on implementing our NYSE American compliance plan while building a stronger financial and operating foundation for the Company over time. We have real technology in the field, a clear operating framework, and a leadership and advisory team focused on disciplined execution.”

The updated presentation also highlights BiomX’s leadership and advisory team, which includes experience across defense technology, public markets, operational security, electro-optics, and large-scale security systems. BiomX believes this experience supports the Company’s ability to evaluate, acquire, and advance technologies that address evolving physical security needs.

About BiomX Inc.

BiomX Inc. is a company focused on acquiring and further developing technologies that identify, track, and respond to physical threats across defense, security, critical infrastructure, and first-response sectors. The Company’s portfolio is built around the growing need for earlier and more accurate threat detection, particularly as UAVs and other autonomous systems play a larger role in defense and homeland security.

Forward-Looking Statements

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements” within the meaning of the federal securities laws, including statements regarding BiomX’s ability to regain compliance with the continued listing standards of the NYSE American, the Company’s ability to execute the initiatives set forth in its compliance plan, the Company’s ability to maintain the listing of its common stock on the NYSE American during the plan period, and the Company’s business strategy, financial position and strategic opportunities. In some cases, you can identify forward-looking statements by terminology such as “will,” “would,” “expect,” “intend,” “plan,” “objective,” “believe,” “anticipate,” or comparable terminology referencing future events, conditions or circumstances, or the negative of such terms.

Although BiomX believes that it has a reasonable basis for the forward-looking statements contained in this press release, they are based on management’s current beliefs and expectations about future events and circumstances and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond the Company’s control. Statements relating to the future performance of BiomX are subject to many factors, including but not limited to the Company’s ability to regain compliance with NYSE American continued listing standards within the applicable plan period, the possibility that NYSE Regulation may initiate delisting proceedings if the Company does not regain compliance or make progress consistent with its compliance plan, the sufficiency of working capital to realize the Company’s business plans and strategic opportunities, the going concern qualification in the Company’s financial statements, the Company’s ability to integrate and further develop acquired technologies, market acceptance and adoption of the Company’s technologies, competitive developments, changes in government and defense spending priorities, regulatory, export-control and geopolitical developments, Israel Innovation Authority restrictions applicable to certain of the Company’s technologies, customer concentration and the Company’s reliance on a limited number of key customer relationships, the Company’s ability to penetrate its intended markets and execute its business strategy, and other risk factors. Risk factors described under “Risk Factors” in BiomX’s most recently filed Annual Report on Form 10-K, as supplemented by the Form 10-K/A filed with the SEC on April 30, 2026, the Current Report on Form 8-K filed with the SEC on May 5, 2026, and other filings with the Securities and Exchange Commission, may cause actual results, performance, or achievements to differ materially from those expressed or implied by forward-looking statements in this press release.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. BiomX undertakes no obligation to update any forward-looking statement contained in this press release to reflect events that occur or circumstances that exist after the date of this press release, except as required by law.

Investor Contact

Yair Ohayon
[email protected]

Issued on behalf of LIXTE Biotechnology Holdings, Inc.

Having entered into definitive documents to combine with NOMAD, LIXTE is set to become NOMAD Power Solutions — a pure-play deployable-power company — and is funding NOMAD with $6.5 million before the deal even closes.

BOCA RATON, Fla., June 18, 2026 (GLOBE NEWSWIRE) — USA News Group News Commentary — Wall Street spent the last two years obsessed with who makes the chips that power artificial intelligence. The smarter money is now asking a more basic question: where will all the electricity come from? AI data centers consume staggering, continuous quantities of power, and the grid that is supposed to feed them cannot expand fast enough to keep up. That gap — between exploding demand and a power system that takes years to build — has become one of the defining bottlenecks of the AI era, and a major investment theme in its own right. One Nasdaq-listed company has now decided to reinvent itself entirely to attack that bottleneck. On June 18, 2026, LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) updated the market on its transformation, having entered into definitive documents to combine with NOMAD, into a pure-play deployable-power company.

Key Takeaways

• A definitive deal that redefines the company: LIXTE has entered into definitive documents to combine with NOMAD Transportable Power Systems and will rename itself NOMAD Power Solutions, Inc., trading on Nasdaq under a new ticker, repositioning as a pure-play deployable-power company focused on the AI-driven power crunch.
• Capital deployed before closing: The company will loan NOMAD $6.5 million ahead of the anticipated close — expected on or about July 1, 2026 — to fund long-lead components and working capital as NOMAD scales to meet its order book.
• A real operating business: NOMAD describes itself as a market leader in deployable, utility-grade battery energy storage systems (BESS) and the first to bring a mobile, utility-grade 1 MW BESS to market, serving utilities, industrial users, and data centers.
• Strong disclosed momentum: NOMAD reported revenue growth of roughly 175% in 2025 with about 135% more projected for 2026, approximately 75% inbound sales, and more than 30 active opportunities across North America.
• Early-stage reality: The deal has not yet closed, and the combined company will be a small player competing against far larger, better-capitalized energy names — a high-potential, high-uncertainty transformation.

A Decisive Reinvention, Not a Diversification

The most important thing to understand about this story is that it is a clean break, not a hedge. By entering into definitive documents to combine with NOMAD Transportable Power Systems — and renaming itself NOMAD Power Solutions, Inc. — LIXTE is reconstituting itself entirely around that operating business. The company has framed the new identity around a “singular focus” on solving the power-availability constraint facing utilities, industrial operators, and the data center market. In plain terms: going forward, this is a power-infrastructure company, full stop, and the investment thesis is the AI-driven demand for reliable, rapidly deployable electricity.

Management is backing that reinvention with capital before the ink is even dry. Rather than wait for the transaction to close, the company will loan NOMAD $6.5 million now — funding the procurement of long-lead components against NOMAD’s order pipeline and supporting working capital as it scales manufacturing. Deploying money ahead of a close is unusual, and it is meant to send a message: management sees demand it does not want to leave unfilled, even for a few weeks. “Putting capital to work now, ahead of closing, reflects our conviction in NOMAD’s platform and attempting to fulfill the demand we are seeing,” said Geordan Pursglove, the company’s chief executive. “This loan allows NOMAD to keep pace with its order book and continue scaling without delay as we move toward completing the transaction.”

Why Power — Not Chips — Is the AI Bottleneck

The logic behind the pivot rests on a problem that has moved to the center of the energy and technology worlds. Training and running large AI models requires enormous, uninterrupted, high-quality power, and the data centers springing up to meet that need are straining electricity grids across multiple regions. The catch is that you cannot simply will new power into existence: building permanent generation and grid infrastructure means navigating land-use entitlements, environmental reviews, local opposition, and interconnection queues that can stretch for years. By the company’s framing, roughly 2.3 terawatts of generation and storage capacity is currently waiting in U.S. interconnection queues — a staggering backlog that captures the mismatch between how fast demand is growing and how slowly fixed power assets come online.

That mismatch is the entire opportunity. If permanent power cannot be built fast enough where it is needed, the next best thing is power that can be moved and switched on quickly — and that is precisely the gap deployable storage is designed to fill. “The acceleration in demand from AI infrastructure and data center customers confirms that deployable, utility-grade storage is becoming an essential layer of the modern grid,” said John Travaglini, chief executive of NOMAD. For data-center operators facing the choice between waiting years for grid power or finding another way, a solution that delivers reliable megawatts in a fraction of the time is not a luxury — it is a lifeline.

What NOMAD Actually Does

NOMAD Transportable Power Systems, based in Waterbury, Vermont, has spent roughly six years building the answer to that problem. The company describes itself as a market leader in deployable, utility-grade battery energy storage systems — BESS — and says it was the first to bring a mobile, utility-grade 1 megawatt BESS to market. The key word is mobile. Many companies build stationary battery storage; NOMAD’s differentiator is that its megawatt-scale platforms are utility-tested, validated to the demanding UL 9540 safety standard, and yet can be transported and deployed in real time — delivered to a site, connected, and producing power on timelines fixed installations cannot match.

Because NOMAD’s systems are deployed as equipment rather than permanent infrastructure, they can often sidestep the permitting and interconnection bottlenecks that strangle traditional power projects, while still meeting the standards utilities demand. The platform already serves investor-owned utilities, electric cooperatives, municipal utilities, government agencies, critical-infrastructure providers, and large industrial energy users — through equipment sales, rentals, and an Energy-as-a-Service model. In data center environments, where even a momentary lapse in power quality can crash a mission-critical AI workload, the combination of utility-grade reliability, near-instantaneous response, and rapid mobile deployment is, in NOMAD’s telling, exactly what the moment demands.

The Numbers Behind the Bet

The pre-closing loan looks far more rational once the growth profile comes into view. According to figures disclosed by the company, NOMAD’s revenue grew approximately 175% year-over-year in 2025, with management projecting roughly 135% additional growth in 2026. Strikingly for a young hardware company, approximately 75% of its sales activity is inbound — customers approaching NOMAD rather than the reverse — and it reports more than 30 active utility, infrastructure, and strategic customer opportunities across North America. Those are the hallmarks of a business racing to keep up with demand rather than working to create it, and they help explain why management is willing to fund the company before formally owning it. Long-lead components — the parts that take months to procure — are precisely what can bottleneck a scaling hardware manufacturer, and funding them early is a bid to keep production moving without interruption.

The Companies It Will Be Measured Against

Once the transaction closes, NOMAD Power Solutions will be judged against a fast-moving group of energy-storage and on-site-power companies that have become some of the most closely watched names in the AI-infrastructure trade. A few help frame both the scale of the opportunity and the competition a newly public power company will face.

Fluence Energy, Inc. (NASDAQ: FLNC) is the grid-scale storage bellwether. A global leader in utility-scale battery storage, Fluence has become a market favorite as AI-driven demand lifts storage names, with supply agreements tied to hyperscalers and a record multibillion-dollar backlog. It operates at a scale far beyond an emerging deployable-power company, but it validates the core thesis NOMAD is built on: utility-grade storage has become strategic infrastructure for the AI era.

Stem, Inc. (NYSE: STEM) comes at storage from the software and intelligence layer, optimizing how batteries are dispatched and how they earn in energy markets. Stem is a useful reference because deployable storage competes on more than hardware — monitoring, optimization, and service matter — and it illustrates the recurring-revenue dimension layered on top of the batteries themselves.

Eos Energy Enterprises, Inc. (NASDAQ: EOSE) represents the long-duration, U.S.-manufactured end of the storage spectrum, commercializing zinc-based systems built domestically. A higher-risk, higher-reward name tied to the same demand surge, Eos underscores how investors are funding a range of storage chemistries — and how a domestic, safety-focused approach has become a selling point, echoing NOMAD’s emphasis on utility-grade, validated systems.

Bloom Energy Corporation (NYSE: BE) attacks the same availability problem with a different technology — on-site fuel cells that generate power directly at a data center or industrial site, bypassing the grid. A leading name in the “bring your own power” movement, Bloom is a reminder that NOMAD competes not only against other battery makers but against an array of approaches to one goal: getting reliable power to where AI needs it, fast. These companies are referenced to illustrate the sector and do not imply any partnership, endorsement, affiliation, or comparable financial performance; they differ widely in size, technology, and stage, and the new NOMAD Power Solutions will be among the smallest and earliest in its public-company life.

The Risks Behind the Reinvention

The thesis is compelling, but the risks are substantial. Most immediately, the transaction has not yet closed: it is expected to complete on or about July 1, 2026, subject to customary closing conditions and required approvals, and there is no guarantee it will close on that timeline — or at all. The $6.5 million pre-closing loan, while a strong signal of conviction, means capital is being committed to a business the company does not yet own. The renaming, the new ticker, and the entire repositioning hinge on completing the transaction.

Beyond deal risk, investors would be underwriting a profound transformation. The combined company will be a small player competing against far larger, better-capitalized energy-storage and power companies, including the names above. NOMAD’s growth rates are company-disclosed and, for 2026, projected — forward-looking figures that may not materialize. Scaling hardware manufacturing is capital-intensive and operationally demanding, exposed to supply-chain disruptions, component costs, and execution risk. As a company reinvented through this transaction, the new entity will have limited operating history in its reconstituted form and will likely require ongoing access to capital. The company’s own forward-looking disclosures catalogue these and other uncertainties, and they deserve serious weight alongside the appeal of the story.

The Bottom Line

The reinvention of LIXTE into NOMAD Power Solutions is a bold, all-in bet on what may be the defining infrastructure problem of the AI era: not the chips, but the power to run them. The macro backdrop is real and intensifying — AI electricity demand is climbing faster than the grid can expand, and the gap between the two is exactly where deployable, utility-grade power becomes valuable. A company that can roll megawatt-scale storage onto a site and energize it in a fraction of the time a permanent build requires is offering a solution tuned to the moment, and the decision to fund NOMAD before the deal even closes is the clearest possible statement of management’s conviction.

Whether the company can convert that conviction into durable commercial scale remains to be proven, and the execution and financing risks are real. But the question it has reorganized itself around — how to deliver reliable power to the AI economy faster than the grid can — is among the most consequential in the market today. For investors tracking where the AI power crunch is headed, a Nasdaq company reinventing itself, by entering into definitive documents to combine with NOMAD, into a pure-play deployable-power business is a transformation worth following closely.

CONTINUED … Learn more about LIXTE Biotechnology Holdings, Inc. at:
https://www.lixte.com

SEE WHAT THE MARKET IS TALKING ABOUT BEFORE IT MOVES

Eagle Eye reads social, forum, and news chatter across thousands of investor conversations in real time — and surfaces the tickers the crowd is piling into, along with the sentiment and catalysts behind them.
Explore Eagle Eye free (for now) at https://Eagle-Eye.dev

CONTACT:

USA News Group
[email protected]
(604) 265-2873

SOURCES:

[1] LIXTE Biotechnology Holdings, Inc. — “LIXTE Biotechnology Provides Update on NOMAD Acquisition; Transaction Expected to Close On or About July 1, 2026” (June 18, 2026; primary source for the $6.5M pre-closing loan, July 1 close, renaming to NOMAD Power Solutions, new ticker, CEO Geordan Pursglove and John Travaglini quotes):
https://ir.lixte.com/news-events

[2] LIXTE Biotechnology Holdings, Inc. — “LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)” (GlobeNewswire, June 12, 2026; 100% acquisition, first mobile utility-grade 1 MW BESS, ~175% 2025 / ~135% 2026 revenue growth, ~75% inbound, 30+ opportunities, permitting advantage, ~2.3 TW queues): 
https://www.globenewswire.com/news-release/2026/06/12/3311039/0/en/lixte-biotechnology-to-acquire-nomad-transportable-power-systems-the-market-leader-in-mobile-utility-grade-battery-energy-storage-systems-bess.html

[3] LIXTE Biotechnology Holdings, Inc. — SEC Form 8-K, Exhibit 99.1 (June 12, 2026; UL 9540 / NFPA 855 / IEEE 1547 standards, deployable architecture, transaction structure):
https://www.sec.gov/Archives/edgar/data/0001335105/000149315226028878/ex99-1.htm

[4] BloombergNEF / Fluence Energy and sector coverage — utility-scale storage market growth and AI-power peer context (Fluence FLNC, Stem STEM, Eos EOSE, Bloom BE): 
https://www.sec.gov/Archives/edgar/data/0001868941/000110465926056304/flnc-20260331x10q.htm

DISCLAIMER:

Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a digital media distribution and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances.
USA News Group is a wholly-owned subsidiary of Market IQ Media Group Limited, a company incorporated under the laws of Ireland (“MIQL”). MIQL has been paid a fee for LIXTE Biotechnology Holdings, Inc. advertising and digital media from Creative Direct Marketing Group (“CDMG”). This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this article or email as the basis for any investment decision. MIQL does not own shares of LIXTE Biotechnology Holdings, Inc. but reserves the right to buy and sell shares of LIXTE Biotechnology Holdings, Inc. at any time without any further notice. There may be 3rd parties who may have shares of LIXTE Biotechnology Holdings, Inc., and may liquidate their shares which could have a negative effect on the price of the stock. We also expect further compensation as an ongoing digital media effort to increase visibility for the company; no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been reviewed and approved on behalf of LIXTE Biotechnology Holdings, Inc. by CDMG; this is a digital media distribution.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our publication is not trustworthy unless verified by their own independent research. Comparisons to other companies referenced in this publication are for contextual and illustrative purposes only and do not imply any partnership, endorsement, affiliation, or comparable financial performance. Forward-looking statements regarding the NOMAD acquisition and its closing, the pre-closing loan, the renaming and ticker change, revenue growth and projections, manufacturing scale-up, customer demand, and market trends are subject to risks and uncertainties, and actual results may differ materially. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.